Verve’s Base Editor “Numerically Beats” Other Cholesterol-Lowering Drugs

In a Phase Ib trial, VERVE-102 showed it could lower bad cholesterol across doses, setting up an opt-in decision for Eli Lilly and a showdown with Novartis.